drugset / Trial / NCT03359460
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
Phase 1
Completed
4 enrolled
University of California, Davis
Celgene Corporation · collabNational Cancer Institute (NCI) · collabPharmacyclics LLC. · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of ibrutinib when giving together with lenalidomide in treating patients with myelodysplastic syndrome. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and lenalidomide may work better in treating patients with myelodysplastic syndrome.
Timeline
- Start
- 2017-12-01
- Primary completion
- 2019-08-29
- Completion
- 2019-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Subject | Lenalidomide | Other / unclassified | — | Oral |